Abstract
Antipsychotic drugs induce extrapyramidal symptoms such as dystonia, akathisia and parkinsonian symptoms early in treatment, and tardive dyskinesia later in treatment. With the advent of atypical antipsychotic drugs, the incidence of extrapyramidal symptoms has decreased, but the danger still exists. There are many reasons that extrapyramidal symptoms are still a problem. Most often, psychiatrists use doses higher than the recommended dose of atypical antipsychotic agents. For example, the use of 8 to 10 mg of risperidone, 30 to 40 mg of olanzapine, or 1200 to 1500 mg of quetiapine daily is not uncommon. In addition, combinations of both conventional and atypical antipsychotic drugs are used together in many instances. Extrapyramidal symptoms produce unnecessary suffering and add to the health burden; therefore, prompt recognition of these symptoms is necessary. If EPS occur, it is of paramount importance to start an antiparkinsonian agent immediately to provide relief to the patient. In high-risk patients, prophylactic antiparkinsonian therapy is indicated but routine prophylaxis with antiparkinsonian agents is harmful. As only a segment of patients may develop EPS, many patients receive prophylactic medication unnecessarily, and the side effects of antiparkinsonian drugs prescribed without clinical indication may add to the health burden of the patient. If prophylactic antiparkinsonian treatment is initiated, it should be discontinued at least two weeks after its initiation. The long term use of antiparkinsonian treatment is not therapeutically beneficial to the patient, and studies indicate that the gradual withdrawal of antiparkinsonian medication will not produce recurrence of EPS.
Keywords: antiparkinsonian agents, treatment of drug induced extrapyramidal symptoms, side effects of antiparkinsonian drugs, controversies regarding the long term use of anticholinergic drugs
Current Pharmaceutical Design
Title: The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Volume: 10 Issue: 18
Author(s): K. Burgyone, K. Aduri, J. Ananth and S. Parameswaran
Affiliation:
Keywords: antiparkinsonian agents, treatment of drug induced extrapyramidal symptoms, side effects of antiparkinsonian drugs, controversies regarding the long term use of anticholinergic drugs
Abstract: Antipsychotic drugs induce extrapyramidal symptoms such as dystonia, akathisia and parkinsonian symptoms early in treatment, and tardive dyskinesia later in treatment. With the advent of atypical antipsychotic drugs, the incidence of extrapyramidal symptoms has decreased, but the danger still exists. There are many reasons that extrapyramidal symptoms are still a problem. Most often, psychiatrists use doses higher than the recommended dose of atypical antipsychotic agents. For example, the use of 8 to 10 mg of risperidone, 30 to 40 mg of olanzapine, or 1200 to 1500 mg of quetiapine daily is not uncommon. In addition, combinations of both conventional and atypical antipsychotic drugs are used together in many instances. Extrapyramidal symptoms produce unnecessary suffering and add to the health burden; therefore, prompt recognition of these symptoms is necessary. If EPS occur, it is of paramount importance to start an antiparkinsonian agent immediately to provide relief to the patient. In high-risk patients, prophylactic antiparkinsonian therapy is indicated but routine prophylaxis with antiparkinsonian agents is harmful. As only a segment of patients may develop EPS, many patients receive prophylactic medication unnecessarily, and the side effects of antiparkinsonian drugs prescribed without clinical indication may add to the health burden of the patient. If prophylactic antiparkinsonian treatment is initiated, it should be discontinued at least two weeks after its initiation. The long term use of antiparkinsonian treatment is not therapeutically beneficial to the patient, and studies indicate that the gradual withdrawal of antiparkinsonian medication will not produce recurrence of EPS.
Export Options
About this article
Cite this article as:
Burgyone K., Aduri K., Ananth J. and Parameswaran S., The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384123
DOI https://dx.doi.org/10.2174/1381612043384123 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Central Nervous System Depressants and Risk of Hospitalization due to Community-Acquired Pneumonia in very Old Patients
Current Drug Safety Risk Factors and Metabolism of Different Brain Regions by Positron Emission Tomography in Parkinson Disease with Disabling Dyskinesia
Current Neurovascular Research Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry The Neuropharmacology of (-)-Stepholidine and its Potential Applications
Current Neuropharmacology Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Current Medicinal Chemistry Serotonin Reuptake Inhibitors: The Corner Stone in Treatment of Depression for Half a Century – A Medicinal Chemistry Survey
Current Topics in Medicinal Chemistry Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Recent Advances in the Development of 14-Alkoxy Substituted Morphinans as Potent and Safer Opioid Analgesics
Current Medicinal Chemistry Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued)